CCI Clears Serum Institute Life Sciences-Biocon Biologics Deal
![](https://healthwire.co/wp-content/uploads/2022/05/Competition_Commission_of_India_1652944410229_1652944410417.jpg)
CCI Approves Merger of Covidshield Technologies into Biocon Biologics, Serum Institute Life Sciences Acquires 15% Equity Shareholding The Competition Commission of India (CCI) approves the merger by absorption of Covidshield…
Share